Who are Non sedating H1-antihistamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azelastine - intranasal application, Diphenhydramine 5%, Fluticasone/Azelastine nasal spray, Olopatadine Nasal Spray, Morphine-Promethazine, Antihistamine Cetirizine Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/non-sedating-h1-antihistamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Non sedating H1-antihistamine — Competitive Intelligence Brief

Non sedating H1-antihistamine (Non sedating H1-antihistamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (non-sedating antihistamine). Area: Allergy/Immunology.

phase 3 H1-receptor antagonist (non-sedating antihistamine) H1 histamine receptor Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Non sedating H1-antihistamine (Non sedating H1-antihistamine) — Sanofi. Selectively blocks H1 histamine receptors on mast cells and basophils without crossing the blood-brain barrier, preventing histamine-mediated allergic responses without causing sedation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Non sedating H1-antihistamine TARGET	Non sedating H1-antihistamine	Sanofi	phase 3	H1-receptor antagonist (non-sedating antihistamine)	H1 histamine receptor
Azelastine - intranasal application	Azelastine - intranasal application	Association Asthma, Bulgaria	marketed	Selective H1-receptor antagonist (intranasal antihistamine)	H1 histamine receptor
Diphenhydramine 5%	Diphenhydramine 5%	Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology	marketed	H1 receptor antagonist (first-generation antihistamine)	H1 histamine receptor
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor
Olopatadine Nasal Spray	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Antihistamine Cetirizine Hydrochloride	Antihistamine Cetirizine Hydrochloride	Goldman, Butterwick, Fitzpatrick and Groff	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (non-sedating antihistamine) class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Non sedating H1-antihistamine — Competitive Intelligence Brief. https://druglandscape.com/ci/non-sedating-h1-antihistamine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab